Patienter, der fik pioglitazon, havde en gennemsnitlig reduktion af HbA1c på 0, 45% sammenlignet med de patienter, der fortsatte på insulin alene, samtidig sås en reduktion af insulin dosis hos de pioglitazon behandlede.
Patients receiving pioglitazone had a mean reduction in HbA1c of 0.45% compared with those continuing on insulin alone, and a reduction of insulin dose in the pioglitazone treated group.